Clinical Analysis of the Short-Term Outcome of Papillary Thyroid Micro Carcinoma After ¹³¹I Treatment

References

• Chinese Association of Thyroid Oncology. Chinese expert consensus on diagnosis and treatment of papillary thyroid microcarcinoma. Chin J Clin Oncol . 2016;43(10):405–411. doi:10.3969/j.issn.1000-8179.2016.10.001
   Google Scholar
• Chinese Society of Nuclear Medicine. Clinical guidelines for 131I therapy of differentiated thyroid cancer (2021). China J Nucl Med Mol Imaging . 2021;41(4):218–241. doi:10.3760/cma.j.cn321828-20201113-00412
   Google Scholar
• Haugen BR , Alexander EK , Bible KC , et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid . 2016;26(1):1–133. doi:10.1089/thy.2015.0020 26462967
   PubMed Web of Science ®Google Scholar
• Thyroid cancer committee of Chinese Society of Clinical Oncology. Expert consensus on preoperative assessment of 131I after operation for differentiated thyroid cancer. China Oncol . 2019;29(10):832–840. doi:10.19401/j.cnki.1007-3639.2019.10.011
   Google Scholar
• Xin Z , Yansong L . Progress of 131I therapy for non distant metastatic differentiated thyroid cancer: interpretation of “ESMO clinical practice guidelines: diagnosis, treatment and follow-up of thyroid cancer” in 2019. China J Nucl Med Mol Imaging . 2020;40(06):343–350. doi:10.3760/cma.j.cn321828-20200220-00056
   Google Scholar
• Calò PG , Medas F , Conzo G , et al. Intraoperative neuromonitoring in thyroid surgery: is the two-staged thyroidectomy justified? Int J Surg . 2017;41(Suppl 1):S13–S20. doi:10.1016/j.ijsu.2017.02.001 28506407
   PubMed Web of Science ®Google Scholar
• Conzo G , Docimo G , Mauriello C , et al. The current status of lymph node dissection in the treatment of papillary thyroid cancer. A literature review. Clin Ter . 2013;164(4):e343–6. PMID: 24045534. doi:10.7417/CT.2013.1599 24045534
   PubMed Web of Science ®Google Scholar
• Jierui L , Jun L , Yansong L . Relationship between preablative stimulated thyroglobulin and the excellent response in differentiated thyroid carcinoma. China Oncol . 2019;29(2):125–130. doi:10.19401/j.cnki.1007-3639.2019.02.005
   Google Scholar
• Mehanna H , Al-Maqbili T , Carter B , et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21 329 person-years of follow-up. J Clin Endocrinol Metab . 2014;99(8):2834–2843. doi:10.1210/jc.2013-2118 24828487
   PubMed Web of Science ®Google Scholar
• Li H , Zhang Y-Q , Wang C , et al. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer. Clin Endocrinol (Oxf) . 2018;88(4):601–606. doi:10.1111/cen.13551 29338092
   PubMed Web of Science ®Google Scholar
• Wang X , Song Q , Dong X . Effects of timing of initial postoperative radioactive iodine therapy on the outcome of patients with differentiated thyroid cancer. J China Med Univ . 2019;48(4):359–369. doi:10.12007/j.issn.0258-4646.2019.04.016
   Google Scholar
• Du F , Hu S , Wu C , et al. Analysis of the factors affecting the efficacy of 131I remnant ablation in patients after thyroidectomy for papillary thyroid microcarcinoma. Chin J Oncol . 2018;40(8):610–613. doi:10.3760/cma.j.issn.0253-3766.2018.08.009
   Google Scholar
• Konturek A , Barczyński M , Nowak W , et al. Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto’s thyroiditis. Langenbecks Arch Surg . 2014;399(2):229–236. doi:10.1007/s00423-013-1158-2 24407910
   PubMed Web of Science ®Google Scholar
• Kwon H , Choi JY , Moon JH , et al. Effect of Hashimoto thyroiditison low-dose radioactive-iodine remnant ablation. Head Neck . 2016;38(Suppl l):E730–735. doi:10.1002/hed.24080 25899980
   PubMed Web of Science ®Google Scholar
• Danyang S , Wei Z , Jian T . Clinical features of lymph node metastasis in papillary thyroid microcarcinoma with 131I treatment. Chin J Endocrinol Metab . 2016;32(11):900–905. doi:10.3760/cma.j.issn.1000-6699.2016.11.003
   Google Scholar
• Li F , Chen G , Sheng C . BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocr Relat Cancer . 2015;22(2):159–168. doi:10.1530/ERC-14-0531 25593071
   PubMed Web of Science ®Google Scholar
• Choi SY , Park H , Kang MK , et al. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol . 2013;11:291. doi:10.1186/1477-7819-11-291 24228637
   PubMed Web of Science ®Google Scholar
• Vrachimis A , Riemann B , Mäder U , et al. Endogenous TSH levels at the time of (131)I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. Eur J Nucl Med Mol Imaging . 2016;43:224–231. doi:10.1007/s00259-015-3223-2 26493309
   PubMed Web of Science ®Google Scholar
• Sohn SY , Choi JY , Jang HW , et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. Thyroid . 2013;23(6):741–747. doi:10.1089/thy.2012.0136 23205883
   PubMed Web of Science ®Google Scholar
• Kim H , Kim SJ , Kim IJ , et al. Limited clinical value of periablative changes of serum markers in the prediction of biochemical remission in patients with papillary thyroid cancer. Nucl Med Mol Imaging . 2013;47(4):268–272. doi:10.1007/s13139-013-0220-x 24900123
   PubMedGoogle Scholar